Immunotherapy for EGFR Mutated Lung Cancer

Patients with non-small cell lung cancer (NSCLC) harboring epidermal growth factor receptor ‎‎(EGFR) mutations face poor outcomes after progression on tyrosine kinase inhibitors (TKIs). ‎The efficacy of immune checkpoint inhibitors (ICIs) combined with chemotherapy in these ‎patients remains uncertain. ‎Therefore, we performed this meta-analysis.